The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Limiting sugar intake could reduce allogeneic hematopoietic cell transplant side effects

Eating less sugar could protect the microbiome during antibiotic treatment, according to a study led by researchers at City of Hope. The study followed patients with blood cancer who were going through an intensive treatment called allogeneic hematopoietic cell transplant. This population is at particularly high risk for severe gut microbiome disruption and associated side effects. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account